KPV 10 mg

How it works

KPV is one of the shortest peptides studied for potential therapeutic relevance: a tripeptide made of lysine, proline, and valine. It corresponds to the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone peptide long studied for its role in immune and inflammatory signaling.^[2]

Because it shares this fragment with alpha-MSH, KPV is discussed almost entirely within anti-inflammatory peptide research rather than as a growth-hormone-related or metabolic compound. It is not a therapeutic protein or an approved drug; it is a small research molecule whose biological interest comes from a mechanistic link to melanocortin biology rather than from any clinical track record of its own.

Benefits & side effects

The most cited KPV research is a 2008 study reporting that PEPT1-mediated uptake of the tripeptide reduced intestinal inflammation in experimental cell and mouse colitis models.^[3] Related work has examined KPV and alpha-MSH-derived fragments in laboratory and animal systems relevant to skin inflammation, wound healing, and cytokine signaling.^[2] This evidence is useful for generating hypotheses, not for establishing a treatment.

Human clinical evidence is absent. In its 2026 source review, FDA found no clinical studies, case reports, or human exposure data for KPV administered by any route.^[17] KPV is not an established treatment for inflammatory bowel disease, psoriasis, dermatitis, wound healing, or any other condition.